Tag Archives: Johnson & Johnson

A Critical Path to New TB Treatments

Image via Wikipedia FDA Commissioner Margaret Hamburg announced, on Thursday, a new joint initiative between industry, FDA, and non-profit organizations designed to fast-track modern combination treatments for tuberculosis. Where once it took more than two decades to create new therapies for TB, this collaboration is expected to produce working treatments in less than six years, […]
Posted in R&D | Also tagged , , , , , , | 2 Comments

Pharma and Haiti: Can Altruism Backfire?

Guest blog by Pharm Exec Europe‘s Jacky Law. Pharma companies are responding swiftly to the recent earthquake in Haiti with millions of dollars in cash and drugs. GlaxoSmithKline boasted, for example, that its initial $1.2 million offering of medicines — mainly oral and topical antibiotics — was on the first airlift to the Caribbean island […]
Posted in Corporate Responsibility, Global, Guest Blog, News | Also tagged , , , , | Leave a comment

Feds Chase Down Faulty Skincare Promos

FDA’s Division of Drug Marketing Communications, this week, posted a slew of warning and untitled letters to pharma firms for misleading skincare advertisements. Johnson & Johnson, Galderma, and Allergan each received a letter documenting complaints ranging from false advertising to unsubstantial efficacy claims. J&J received a violation letter in response to a journal ad for […]
Posted in FDA, Marketing | Also tagged , , , | 2 Comments

Merck/Schering-Plough Merger Highlights (Update 1)

Merck and Schering-Plough’s CEOs are giving a run down of the benefits of the $41.1 billion merger, announced this morning, in a conference call with investors. Here are some of the highlights: • Total price of the sale will be $41.1 billion or $23.6 per Schering share. • This deal is structured as a reverse […]
Posted in Deals, Strategy | Also tagged , , , , , | 4 Comments

Pharm Exec Podcast Series:
Bill Trombetta Industry Audit (Part 3)

[display_podcast] Continuing Pharm Exec editor Patrick Clinton’s conversation with Bill Trombetta on the top four pharma companies and what makes them special. Johnson & Johnson: A perennial member of the Top Four, J&J defies the conventional wisdom; it’s a big company that still manages to grow, a sprawling, diversified company that still has focus. And […]
Posted in Podcasts, Strategy | Also tagged , | Leave a comment
  • Categories

  • Meta